Eli Lilly: new indication for diabetes drug Trulicity

(CercleFinance.com) - Eli Lilly said on Monday that the US Food and Drug Administration has approved its drug Trulicity to reduce cardiovascular events in adults with and without established cardiovascular disease.


The injectable drug has been approved for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, it said.

This decision makes Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of cardiovascular events for both primary and secondary prevention populations, Lilly said.

Over 415 million people have type 2 diabetes globally, which is itself a cardiovascular risk factor.

Copyright (c) 2020 CercleFinance.com. All rights reserved.